Company profile
Find cancer quickly & efficiently with MRI and artificial intelligence (AI)
Lucida Medical enables healthcare professionals to find cancer quickly & efficiently with artificial intelligence (AI) and magnetic resonance imaging (MRI)
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CS01 | Transaction MzUyNzc4MzAxM2FkaXF6a2N4
Published 22 Jun 2026 13:46
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0MjYwNDczN2FkaXF6a2N4
Published 11 Nov 2024 08:41
Company registered at Companies House
1 Dec 2023 to 28 Feb 2026
Prostate cancer is the commonest male cancer and second leading cause of cancer death among men in the UK, with over 12,000 UK deaths annually. Lucida Medical will work in partnership with Hampshire Hospitals NHSFT and the University of Cambridge to develop and validate Pi, a novel decision support and precision medicine software platform for the prostate...
